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Abstract
Background: Opportunistic infections and malignancies such as malignant lymphoma and Kaposi sarcoma are
significant complications of human immunodeficiency virus (HIV) infection. However, following the introduction of
antiretroviral therapy in Japan in 1997, the incidence of clinical complications has decreased. In the present study,
autopsy cases of HIV infection in Japan were retrospectively investigated to reveal the prevalence of opportunistic
infections and malignancies.
Methods: A total of 225 autopsy cases of HIV infection identified at 4 Japanese hospitals from 1985–2012 were
retrospectively reviewed. Clinical data were collected from patient medical records.
Results: Mean CD4 counts of patients were 77.0 cells/μL in patients who received any antiretroviral therapy during
their lives (ART (+) patients) and 39.6 cells/μL in naïve patients (ART (−) patients). Cytomegalovirus infection (142
cases, 63.1%) and pneumocystis pneumonia (66 cases, 29.3%) were the most frequent opportunistic infections, and
their prevalence was significantly lower in ART (+) patients than ART (−) patients. Non-Hodgkin lymphoma and
Kaposi sarcoma were observed in 30.1% and 16.2% of ART (−) patients, and 37.9% and 15.2% of ART (+) patients,
respectively. Malignant lymphoma was the most frequent cause of death, followed by cytomegalovirus infection
regardless of ART. Non-acquired immunodeficiency syndrome (AIDS)-defining cancers such as liver and lung cancer
caused death more frequently in ART (+) patients (9.1%) than in ART (−) patients (1.5%; P = 0.026).
Conclusions: The prevalence of infectious diseases and malignancies were revealed in autopsy cases of HIV
infection in Japan. The prevalence of cytomegalovirus infection and pneumocystis pneumonia at autopsy were
lower in ART (+) patients than ART (−) patients. Higher prevalence of non-AIDS defining malignancies among ART
(+) patients than ART (−) patients suggests that onsets of various opportunistic infections and malignancies should
be carefully monitored regardless of whether the patient is receiving ART.
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Background
Opportunistic infections such as Pneumocystis jirovecii
pneumonia (PCP), cytomegalovirus (CMV), non-tuber
culous mycobacteria (NTM), and fungal infections are
frequently found in patients with acquired immunodefi-
ciency syndrome (AIDS) [1]. The most frequent opportun-
istic infection among patients with AIDS is CMV infection,
which commonly causes retinitis, pneumonia, and gastro-
intestinal tract ulcers. PCP is also a frequent infectious
disease in the lungs of patients with AIDS. Additionally,
malignancies such as non-Hodgkin lymphoma (NHL)
and Kaposi sarcoma (KS) are significant complications.
NHL in particular is not easily controlled and is a frequent
AIDS-associated cause of death. Interestingly, KS has only
been reported in homosexual patients, and patients with
multifocal KS lesions have a poor prognosis.
The introduction of antiretroviral therapy (ART) has
drastically changed the incidence of opportunistic infec-
tions in patients infected with human immunodeficiency
virus 1 (HIV-1), resulting in a decline in mortality rates
[2-7]. ART has decreased the frequencies of CMV, PCP,
and NTM infections in patients with AIDS [7]; however,
the frequency of NHL has not changed dramatically [8].
Additionally, non-AIDS-defining malignancies such as liver,
lung, and gastric cancers have been observed in patients
with AIDS, regardless of ART [9]. A recent study demon-
strated that low CD4 counts at ART initiation was asso-
ciated with a greater risk of KS and lymphoma, whereas
other cancers increased over time with ART, likely reflect-
ing an increased risk of cancer with aging [10], low CD4
counts, and cigarette smoking [11-13].
Although mortality rates have decreased dramatically
with the use of ART, its effect in many patients with AIDS
is limited, and AIDS-associated complications remain a
leading cause of death [14,15]. Additionally, untreated HIV-
1-positive patients with severe AIDS-defining illnesses
frequently visit hospitals and often rapidly succumb to
suddenly aggressive progression of their illness [16,17].
Systematic pathological analysis of autopsy cases can
provide useful information related to the cause of death
and the distribution of pathogens in patients. However,
there have been few reports describing the prevalence of
infectious diseases and malignancies in autopsied patients
with HIV infection [1,18]. A previous study using samples
from autopsied patients with HIV infection during 1982–
1998 demonstrated the prevalence of CMV, PCP, and
NTM infections decreased during the study period [18].
The same study reported that, although the prevalence
of KS was unchanged, the prevalence of NHL increased
during the study period [18]. To the best of our know-
ledge, there are no reports demonstrating changes in
the prevalence of opportunistic infections in autopsy
cases of HIV infection following the introduction of ART
after 2000.
In the present study, autopsy cases of HIV infection in
Japan were retrospectively investigated to determine the
prevalence of opportunistic infections and malignancies
often found in patients with AIDS, including non-AIDS-
defining malignancies. Additionally, the association of
ART use with the prevalence of opportunistic infections
and malignancies was investigated.
Patients and methods
Patients
The present study was approved by the Institutional
Review Board of the National Institute of Infectious
Diseases (Approval No. 356) and of four hospitals in Japan:
Tokyo Metropolitan Komagome Hospital, National Center
for Global Health and Medicine, Research Hospital, the
Institute of Medical Science, the University of Tokyo,
and Osaka National Hospital. Each hospital enrolled in the
present study is a central hospital for AIDS treatment in
Tokyo and Osaka, and has performed more than 15 autop-
sies of patients infected with HIV. According to a national
autopsy survey by the Japan Pathology Society, 828 patients
infected with HIV were autopsied in Japan from 1987–
2009. During the period 1985–2009, 215 patients infected
with HIV were autopsied at the 4 aforementioned hospi-
tals. Thus, the number of cases in this study covered ap-
proximately 26% of all autopsied HIV cases. Ten cases
autopsied in the period 2010–2012 were added to the
215 cases, making a total of 225 patients analyzed in this
study (Table 1), of which 95.1% were male. The patients’
ages at death ranged from 12 to 80 years, with a mean
age of 44.4 years (median 44 years). Among them, 35.6%
were homosexual, and 29.3% received ART (Table 1).
The mean CD4 count at the last blood examination before
death was 51.5 cells/μL (range: 0–560 cells/μL; median:
13.5 cells/μL). ART was introduced in Japan in 1997. In this
study, ART was defined as any combination of therapy that
included two nucleoside or nucleotide reverse transcriptase
inhibitors plus a non-nucleoside reverse transcriptase in-
hibitor, protease inhibitor, or abacavir (another nucleotide
reverse transcriptase inhibitor). Additionally, ART (+)
patients were defined as patients who received any ART
during their lifetime, whereas ART (−) patients were as
patients who did not receive ART.
Methods
Pathological findings were collected from autopsy re-
cords. CMV infection was determined by the infiltration
of large cells with typical inclusion bodies. Infections by
other viral agents such as hepatitis B virus, herpes simplex
virus, hepatitis C virus, JC virus (causing progressive multi-
focal leukoencephalopathy), and varicella zoster virus
were confirmed by immunohistochemistry or polymer-
ase chain reaction. HIV encephalopathy was defined by
morphological features indicating the presence of syncytial
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Table 1 Characteristics of the patients infected with HIV
Factors Groupings Total patients ART (−) patients ART (+) patients P value
n % n % n %
Total 225* 100% 136 100% 66 100%
Sex Male 214 95.1% 128 94.1% 63 95.5% 0.695**
Female 11 4.9% 8 5.9% 3 4.5%
Age at death <10 years 0 0.0% 0 0.0% 0 0.0% 0.028***
11–20 2 0.9% 2 1.5% 0 0.0%
21–30 30 13.3% 22 16.2% 6 9.1%
31–40 60 26.7% 34 25.0% 19 28.8%
41–50 69 30.7% 48 35.3% 14 21.2%
51–60 34 15.1% 18 13.2% 14 21.2%
61–70 24 10.7% 10 7.4% 10 15.2%
71–80 5 2.2% 1 0.7% 3 4.5%
>81 0 0.0% 0 0.0% 0 0.0%
Unknown 1 0.4% 1 0.7% 0 0.0%
Risk factor Homosexual 80 35.6% 52 38.2% 24 36.4% 0.800**
Heterosexual 38 16.9% 24 17.6% 10 15.2%
Blood product 37 16.4% 29 21.3% 7 10.6%
Other 9 4.0% 5 3.7% 4 6.1%
Unknown 61 27.1% 26 19.1% 21 31.8%
CD4 count before death <50 cells/μL 122 54.2% 80 58.8% 33 50.0% 0.639***
51–100 25 11.1% 11 8.1% 14 21.2%
101–200 13 5.8% 4 2.9% 9 13.6%
201–300 5 2.2% 5 3.7% 0 0.0%
301–400 3 1.3% 1 0.7% 2 3.0%
>401 4 1.8% 1 0.7% 3 4.5%
Unknown 53 23.6% 34 25.0% 5 7.6%
ART, antiretroviral therapy. ART (+) patients were defined as patients who received any ART during their lifetime, whereas ART (−) patients were as patients who
did not receive any ART in their lifetime.
*Total number of patients = 225 and included 23 patients with unknown ART status.
**P values were calculated for the rates of male or homosexuals between ART (−) and (+) patients by Chi-square test.
***P values were calculated for age or CD4 counts between all ART (−) and (+) patients by Mann–Whitney U-test. Bold font indicates statistical significance.
Figure 1 Annual number and mean age of AIDS-related autopsies. The solid line indicates total number of AIDS autopsies in each year. The
gray area indicates the number of patients on ART in these autopsy cases. The broken bar indicates the mean age.
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giant cells and detection of HIV-1 antigen by immuno-
histochemistry in the brain. Bacterial infection was identi-
fied by Gram stain, and in some cases, species of bacteria
were identified by bacterial cultures. Tuberculosis and
NTM infection were determined by acid-fast stain and/
or PCR. Fungal and protozoan infections such as PCP,
toxoplasma, Candida, Aspergillus, and Cryptococcus in-
fection, were determined morphologically using Grocott’s
methenamine silver stain, periodic acid-Schiff stain, or/
and immunohistochemistry. The histological sub-typing
of malignant lymphoma was based on the World Health
Organization classification, fourth edition. KS was con-
firmed by immunohistochemistry for Kaposi sarcoma-
associated herpesvirus-encoded latency-associated nuclear
antigen 1. Causes of death were determined by pathologists
at each hospital based on the severity, distribution, and
type of illness in the pathological findings of autopsy. Clin-
ical data, such as age at autopsy, sex, risk factors, CD4 cell
counts at the last blood examination before death, and use
of ART in their lifetime were collected from medical re-
cords. Analysis of statistical significance was carried out
using Mann–Whitney U-test for non-parametric two-
sample analysis and Chi-squared test for contingency table
analysis.
Results
After the introduction of ART in Japan in 1997, the total
number of autopsies conducted on patients with HIV in-
fection has slowly decreased whereas the mean age at
autopsy has increased slightly (Figure 1). After 1997, 66
Table 2 Infectious diseases and malignancies in AIDS-associated autopsies
All patients ART (−) patients ART (+) patients
n % n % n % P values
Total 225 100.0% 136 100.0% 66 100.0%
Infectious diseases
Cytomegalovirus 142 63.1% 97 71.3% 25 37.9% <0.001
Pneumocystis jirovecii pneumonia 66 29.3% 43 31.6% 11 16.7% 0.024
Non-tuberculous mycobacterium 31 13.8% 20 14.7% 8 12.1% 0.618
Candida 25 11.1% 17 12.5% 6 9.1% 0.474
Aspergillus 24 10.7% 17 12.5% 4 6.1% 0.160
Human immunodeficiency virus encephalopathy 21 9.3% 13 9.6% 6 9.1% 0.915
Cryptococcus 16 7.1% 11 8.1% 3 4.5% 0.526 Y
Hepatitis B virus 12 5.3% 6 4.4% 5 7.6% 0.549 Y
Herpes simplex virus 12 5.3% 1 0.7% 1 1.5% 0.816 Y
Toxoplasmosis 11 4.9% 9 6.6% 3 4.5% 0.789 Y
Hepatitis C virus 9 4.0% 3 2.2% 5 7.6% 0.147 Y
Progressive multifocal leukoencephalopathy 8 3.6% 4 2.9% 2 3.0% 0.684 Y
Tuberculosis 6 2.7% 4 2.9% 0 0.0% 0.385 Y
Varicella zoster virus 4 1.8% 2 1.5% 2 3.0% 0.835 Y
Multicentric Castleman disease 2 0.9% 1 0.7% 1 1.5% 0.816 Y
Malignancies
Non Hodgkin lymphoma 71 31.6% 41 30.1% 25 37.9% 0.272
Kaposi sarcoma 38 16.9% 22 16.2% 10 15.2% 0.852
Endocervical cancer 0 0.0% 0 0.0% 0 0.0% –
Non-AIDS defining malignancies 20 8.9% 10 7.4% 10 15.2% 0.082
Hepatic cancer 8 3.6% 4 2.9% 4 6.1% 0.495 Y
Lung cancer 6 2.7% 2 1.5% 4 6.1% 0.174 Y
Leukemia 2 0.9% 0 0.0% 2 3.0% 0.200 Y
Hodgkin lymphoma 2 0.9% 1 0.7% 1 1.5% 0.816 Y
Gastric cancer 1 0.4% 1 0.7% 0 0.0% 0.711 Y
Other cancer 3 1.3% 3 2.2% 0 0.0% 0.551 Y
P values were calculated by Chi-square test. Y indicates the use of Chi-square test with Yates correction. Bold font indicates statistical significance. ART, antiretroviral
therapy. Because more than one illness was detected in patients, the numbers of all illness are greater than the total number.
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of 126 patients (52.6%) received ART during their life-
time. The mean age at death of patients on ART was
47.3 years, which was significantly higher than that of
ART naïve patients (42.6 years; P = 0.028; Mann–Whitney
U-test). Mean CD4 counts of ART (−) and (+) patients at
the last blood examination before death were not sig-
nificantly different (39.6 and 77.0 cells/μL, respectively,
P = 0.63, Mann–Whitney U-test).
CMV was the most commonly identified pathogen
among the autopsy cases (Table 2) and was detected in
various organs, the most frequent being the adrenal gland
(Figure 2A). PCP and NTM were also common pathogens
found in the lungs of autopsied patients. Candida albicans
was frequently detected in the gastrointestinal tract and
oral cavity (Figure 2B). The prevalence of CMV and PCP
was significantly lower in ART (+) patients than in ART (−)
patients (Table 2). There was no significant difference in
the prevalence of other opportunistic infections such as
NTM and Candida or prevalence of HIV encephalopathy
between ART (+) and (−) patients (Table 2).
Malignancies were identified in 50.2% (113/225) of all
cases (Table 2). NHL was the most frequent malignancy
with a lower prevalence in ART (−) patients (30.1%) than
ART (+) patients (37.9%); however, the difference was not
significant (Table 2). Diffuse large B-cell lymphoma was
the most frequent histological subtype of NHL followed by
Burkitt lymphoma, primary effusion lymphoma, and plas-
mablastic lymphoma (Table 3). Epstein–Barr virus positiv-
ity in lymphoma cases was significantly lower in ART (+)
patients compared with ART (−) patients (P = 0.001, Chi-
square test). KS was frequently found in the skin as well as
other sites such as the gastrointestinal tract upon autopsy.
In addition to NHL and KS, non-AIDS-defining malig-
nancies such as Hodgkin lymphoma (HL), hepatic cancer,
lung cancer, and leukemia were also observed in 20 pa-
tients. The prevalence of non-AIDS-defining malignancies
was higher in ART (+) patients compared with ART (−)
patients (Table 2).
The lung was the most frequent target for pathogens in
patients with AIDS and 173 (76.9%) autopsy cases demon-
strated the presence of lung-related illnesses (Table 4),
which were significantly more frequent in ART (−) pa-
tients (112/136, 82.4%) than ART (+) patients (42/66,
63.6%) (P = 0.003, Chi-square test). CMV then PCP was
the most frequently observed lung-related illnesses. The
brain was the second most frequently affected organ in
the autopsy cases. Although the brain was not investigated
in 53 autopsies, 85 of the remaining 172 cases (49.4%)
had brain-related illnesses, with CMV infection the most
common, followed by lymphoma and HIV encephalopathy
(Table 5). However, there was no significant difference
in the rate of brain-related illnesses in ART (+) (37.8%,
17 of 45) or ART (−) patients (52.7%, 58/110) (P = 0.091,
Chi-square test).
We also investigated the direct causes of death in the
autopsied patients (Table 6). Lymphoma was the most
frequent cause of death, followed by CMV infection. Non
AIDS-defining cancers as a cause of death were signifi-
cantly different between ART (−) (2, 1.5%) and ART (+)
patients (6, 9.1%) (P = 0.026; Chi-square test with Yates
correction). The prevalence of CMV, pneumonia, PCP, and
NTM as a cause of death were lower in ART (+) patients
compared with ART (−) patients, but no significant differ-
ences were observed between the groups.
Discussion
In the present study, we measured the prevalence of
infectious disease and malignancy in autopsy cases of
Figure 2 Distribution of cytomegalovirus and Candida albicans. (A) CMV positive rate in each organ. Black bar indicates the CMV positive
rate in each organ from 142 CMV-positive patients. Because CMV was detected in more than one organ per patient, the sum of the black bars is
over 100%. (B) The positive rate of Candida albicans in each organ. Black bar indicates the positive rate of Candida albicans per organ from 25
Candida albicans-positive patients.
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HIV-infected patients identified from 1985–2012 at four
central hospitals in Japan. CMV infection, PCP, NTM
infection, NHL, and KS were frequently observed in the
autopsy cases. The prevalence of CMV and PCP was
lower in ART (−) patients compared with ART (+) pa-
tients. The prevalence of non-AIDS defining malignancies
was higher among ART (+) patients than ART (−) pa-
tients, suggesting that the onset of various opportunistic
infections and malignancies should be carefully monitored
regardless of whether the patient is receiving ART.
The autopsy cases in the present study were predom-
inantly male (95.1%, Table 1). Additionally, more than
70% of the autopsy cases in the present study had a CD4
count < 200 cells/μL at the last blood examination before
death (Table 1). A recent clinical study demonstrated
the incidence of AIDS-defining illnesses in patients with
HIV infection was decreased by the introduction of ART,
especially in patients with CD4 counts >200 cells/μL [2].
Thus, our findings at autopsy cannot be compared with
previous clinical studies because many clinical study pa-
tients had a high range of CD4 counts and ART responses.
Interestingly, there was no significant difference in the
Table 3 Non-Hodgkin lymphoma and Kaposi sarcoma in AIDS-associated autopsies
Total ART (−) patients ART (+) patients P values
n % n % n %
All NHL cases 71 100.0% 41 100.0% 25 100.0%
Histology DLBCL 53 74.6% 30 73.2% 18 72.0% 0.917
BL 4 5.6% 3 7.3% 1 4.0% 0.987 Y
PEL 5 7.0% 4 9.8% 1 4.0% 0.706 Y
PBL 1 1.4% 1 2.4% 0 0.0% 0.801 Y
Other 6 8.5% 2 4.9% 4 16.0% 0.279 Y
Unknown 2 2.8% 1 2.4% 1 4.0% 0.703 Y
Site Nodular 1 1.4% 0 0.0% 1 4.0% 0.801 Y
Extranodular 45 63.4% 28 68.3% 12 48.0% 0.102
Both 21 29.6% 11 26.8% 10 40.0% 0.265
Unknown 4 5.6% 2 4.9% 2 8.0% 0.987 Y
PCNS Yes 27 38.0% 18 43.9% 6 24.0% 0.103
EBV Positive 52 73.2% 35 85.4% 12 48.0% 0.001
KSHV Positive 6 8.5% 5 12.2% 1 4.0% 0.495 Y
Cause of death Yes 50 70.4% 33 80.5% 16 64.0% 0.137
All KS cases 38 22 10
Site Skin 32 84.2% 19 86.4% 9 90.0% 0.410
GI tract 27 71.1% 15 68.2% 8 80.0% 0.705
Lung 21 55.3% 11 50.0% 6 60.0% 0.799
Lymph node 20 52.6% 13 59.1% 6 60.0% 0.502
Other 16 42.1% 0 0.0% 0 0.0% 0.787 Y
Cause of death Yes 11 29.0% 7 31.8% 2 20.0% 0.791 Y
NHL, Non-Hodgkin lymphoma; DLBCL, diffuse large B-cell lymphoma; BL, Burkitt lymphoma; PEL, primary effusion lymphoma; PBL, plasmablastic lymphoma; PCNS,
primary central nervous system lymphoma; EBV, Epstein–Barr virus; KSHV, Kaposi sarcoma-associated herpes virus; KS, Kaposi sarcoma; GI, gastrointestinal. P values
were calculated by Chi-square test. Y indicates the use of Chi-square test with Yates correction. Bold font indicates statistical significance.
Table 4 Lung disease in patients infected with HIV
Illness n % of total patients
(n = 225)
Any illness 173 76.9%
Cytomegalovirus infection 93 41.3%
Pneumocystis jirovecii pneumonia 66 29.3%
Any bacterial pneumonia 31 13.8%
Aspergillus infection 23 10.2%
Kaposi sarcoma 21 9.3%
Non-tuberculous mycobacterium infection 14 6.2%
Cryptococcosis 11 4.9%
Candida infection 10 4.4%
Tuberculosis 4 1.8%
Because more than one illness was detected in patients, the numbers of all
illness are greater than the total number.
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cause of death between ART (+) and (−) patients, with
the exception of those with cancer (Table 6), indicating
the prevalence of lethal illness did not differ between
ART (+) and (−) patients.
Malignancies were frequent causes of death in the present
study regardless of ART status (Table 6). Several studies
demonstrated that the introduction of ART reduced
the incidence of NHL in patients with HIV infection
[13,15,19-23]. The use of ART has also been associated
with a decrease in the incidence of KS [15,24,25]. However,
an association between the incidence of non-AIDS-defining
cancers and ART remains controversial. An increase of
non-AIDS-defining cancers in patients receiving ART was
shown in previous clinical reports [26,27], but a separate
study showed that, with the exception of long-term prote-
ase inhibitor usage, ART exposure was generally not associ-
ated with a risk of non-AIDS-defining cancers [28]. The
reasons for increased risk of non-AIDS-defining cancers in
patients on ARTare unclear, but might reflect the concomi-
tant increase of the mean age at autopsy during the study
period. This suggests that life extension of HIV-infected
patients by ART results in the increased chance of devel-
oping non-AIDS events and malignancies. It was also
Table 5 Brain disease in patients infected with HIV
Illness n % in total
autopsied brains
(n = 172)
Any illness 85 49.4%
Cytomegalovirus infection 45 26.1%
Malignant lymphoma 26 15.1%








Aspergillus infection 2 1.2%
Varicella zoster virus infection 2 1.2%
Herpes simplex virus infection 1 0.6%
Glioblastoma 1 0.6%
Candida infection 1 0.6%
Because more than one illness was detected in patients, the numbers of all
illness are greater than the total number.
Table 6 Cause of death in AIDS-associated autopsies
All ART (−) patients ART (+) patients
n % n % n % P values
Total* 225 100.0% 136 100.0% 66 100.0%
Malignant lymphoma 50 22.2% 33 24.3% 16 24.2% 0.997
Cytomegalovirus 44 19.6% 27 19.9% 9 13.6% 0.279
Pneumonia 31 13.8% 19 14.0% 9 13.6% 0.949
Pneumocystis jirovecii pneumonia 30 13.3% 21 15.4% 4 6.1% 0.058
Non-tuberculous mycobacterium 12 5.3% 10 7.4% 2 3.0% 0.367 Y
Kaposi sarcoma 11 4.9% 7 5.1% 2 3.0% 0.749 Y
Progressive multifocal leukoencephalopathy 8 3.6% 4 2.9% 2 3.0% 0.684 Y
Cancer 8 3.6% 2 1.5% 6 9.1% 0.026 Y
Hepatitis 8 3.6% 3 2.2% 4 6.1% 0.320 Y
Cryptococcus 7 3.1% 6 4.4% 0 0.0% 0.197 Y
Kidney failure 7 3.1% 4 2.9% 3 4.5% 0.861 Y
HIV encephalopathy 7 3.1% 5 3.7% 2 3.0% 0.861 Y
Aspergillus 6 2.7% 5 3.7% 0 0.0% 0.274 Y
Toxoplasmosis 4 1.8% 3 2.2% 1 1.5% 0.835 Y
Tuberculosis 3 0.9% 2 1.5% 0 0.0% 0.816 Y
Sepsis 3 1.3% 2 1.5% 1 1.5% 0.551 Y
Candida 3 1.3% 2 1.5% 0 0.0% 0.816 Y
Varicella zoster virus 2 1.3% 1 0.7% 1 1.5% 0.816 Y
Nocardia 1 0.4% 1 0.7% 0 0.0% 0.711 Y
Histoplasma 1 0.4% 1 0.7% 0 0.0% 0.711 Y
*Because more than one illness was detected in patients, the numbers of all illness are greater than the total number.
HIV, human immunodeficiency virus. P values were calculated with the Chi-square test. Y indicates the use of Chi-square test with Yates correction. Bold font
indicates statistical significance.
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demonstrated that ART introduction changed the patho-
logical features of lymphoma; for example, a decrease of
Epstein–Barr virus-positive lymphoma in Japanese patients
with AIDS was reported [29]. Although HL was rare in
the general Japanese population compared with European
countries and the United States [30], the incidence of HL
increased in Japanese patients on ART [17]. Thus, the in-
creased risk of malignancies during the clinical course of
HIV infection in patients receiving ART was reflected as a
cause of death in the autopsy cases used in our study.
The prevalence of opportunistic infections differs among
various regions and countries. In sub-Saharan African
countries, more than 80% of HIV-positive patients die of
infectious diseases, with disseminated tuberculosis being
the most common (36%) [31]. Furthermore, there was no
difference in the type of disease HIV patients succumbed
to, regardless of ART status. In the USA and European
countries, tuberculosis/NTM represented <10% of mortal-
ity in autopsy cases after 1996 [18]. In this study, tubercu-
losis was detected in only 2.7% of Japanese autopsy cases,
but was the cause of death for 50% of afflicted patients.
Mortality by PCP has decreased worldwide in patients with
AIDS owing to prophylactic administration of an anti-PCP
drug [16]. PCP was found in 36.4% (36/99 cases) of pa-
tients with AIDS before 1997, but was significantly reduced
after 1997 (23.8%; 30/126 cases; P = 0.04; Chi-square test).
This suggests that the decrease in PCP cases is associated
with ARTand anti-PCP prophylaxis.
Our study had several limitations. Bacterial culture was
not available in this study owing to the use of formalin-
fixed paraffin-embedded samples, and it was therefore dif-
ficult to identify the bacterial species responsible for many
cases of pneumonia. Additionally, clinical information was
limited. Information on HIV-RNA, an important indicator
of ART effects, was not available for these patients. In
addition, information regarding CD4 counts and the type,
duration and possible interruption of ART were not avail-
able for a subset of patients. Therefore, we could not iden-
tify cases of immune reconstitution syndrome. Age at
seroconversion and time living with HIV are also major
predictors of HIV disease progression, however infor-
mation of these parameters was limited. Thus, it should
be noted that the conclusions in this study cannot be
generally applied to the current HIV positive population
in Japan. Furthermore, all findings in this study were
obtained from autopsies.
Conclusions
Although further studies are required to demonstrate the
association between ART and illness identified at autopsy,
the present study demonstrates the prevalence of infec-
tious diseases and malignancies in autopsy cases of HIV
infection in Japan. While the prevalence of CMV infection
and PCP at autopsy were lower in ART (+) patients than
ART (−) patients, non-AIDS–defining malignancies were
observed as a cause of death more frequently in ART (+)
patients than ART (−) patients.
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